Top Stories

Do you providecompanies with innovative solutions to improve supply chain efficiency?
In addition to our primary packaging for solid doses, unit dose packaging and secondary packaging services, we also provide integrated supply chain services, such as postponement packaging or late-stage customisation to help our customers cope with small-scale market requirements.

In June 2017, the FDA announced that it will delay the active enforcement of the Drug Supply Chain Security Act (DSCSA) for pharmaceutical manufacturers to November 2018 due to industry-wide concerns that many members of the pharmaceutical supply chain are behind in implementing serialization systems and processes. 

The Zika virus is considered a major global health risk, as infection during pregnancy is associated with babies born with microcephaly.

The numbers are daunting – 15% of the global population suffers from hearing loss, including a significant number of children, teenagers, and the elderly. Hearing loss presents a growing public health problem, due to ageing and an urban way of life that features excessive noise exposure.

The average cost of bringing a new drug to market is $2.6 billion, according to a 2014 report published by Tufts Center for the Study of Drug Development. This is a rise of 145%, adjusted for inflation, compared to just a decade earlier and is driven in part by the increasing complexity of clinical trials.

Biotechnology and pharmaceutical companies within the United States and Europe face an increasing number of hurdles when undertaking clinical trials within their own country or region; problems such as over saturated patient pools, difficulties meeting and maintaining enrollment numbers, increasing costs and lengthy time delays.

View Previous Issues:   Jul'16 | Nov'16 | Apr'17| Aug'17

Upcoming Events

News & Press Releases

BioGenes GmbH, specializing in ELISA development and production and a global leader in host cell protein (HCP) assay development, today announces the establishment of a Scientific Advisory Board which includes the following four renowned experts:

Slovakia-based contract development and manufacturing organization (CDMO) Saneca Pharma has strengthened its team with the appointment of a new CDMO sales director as it continues to implement its global growth strategy.

With nearly 30 years’ experience in the industry, having held positions in a number of worldwide CDMO and contract research companies, Markus Saal joins the senior team at Saneca to head up its finished dosage form (FDF) sales and business development activity.

In addition to being a leading global contract development and manufacturing organization, Vetter is also a leader in the area of occupational health management.

Thrombolytic Science, LLC (TSI), a clinical stage vascular health and biotechnology company announced the appointment of Annalisa Jenkins, MBBS, FRCP, formerly President and CEO of Dimension Therapeutics, Inc. , as a non-executive board member.  Dr. Jenkins brings over 25 years of global pharmaceutical industry experience to TSI’s Board of Directors.

Scientists and doctors from Singapore institutes are collaborating with Samsung Medical Center (SMC), a leading academic medical centre in Seoul, Republic of Korea, to develop the world's first clinically reliable and robust platform that will significantly improve the treatment of hepatocellular carcinoma (HCC) or liver cancer.

Envigo, a leading provider of nonclinical contract research services and research models, announced today the implementation of a first-in-class surgical model tracking system, designed to track and monitor the entire spectrum of surgical model development – enabling critically required efficiencies while enhancing animal welfare.

Subscribe to our Newsletter
captcha 

NorthSea Therapeutics B.V. , a newly established Dutch biotech company, announced the completion of a €25m Series A funding for the development of icosabutate, a structurally engineered fatty acid (‘SEFA’) as a novel, oral approach for the treatment of non-alcoholic steatohepatitis (‘NASH’).

Agendia, a world leader in personalized medicine and molecular cancer diagnostics, and Institute Curie in Paris, France, a leading player in the fight against cancer.

Torque, an immuno-oncology company developing Deep Primed cell therapies that direct and evoke immune responses in the tumor microenvironment, announced the launch of its technology platform to create a new class of immune cell therapeutics to treat cancer, financed with $25 million in Series A capital by Flagship Pioneering.

Eisai Co .Ltd. announced that a presentation on the updated analysis of a global Phase Ib/II clinical study (ENHANCE 1 / Study 218) of its in-house discovered and developed anticancer agent eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: Halaven, eribulin).

OSE Immunotherapeutics announces that the Independent Data Monitoring Committee (IDMC) has recommended to the trial’s steering committee that accrual of the Tedopi® Phase 3 trial for the treatment of advanced non-small cell lung cancer (NSCLC) could resume with a specified new recruitment strategy focused on a subgroup of patients who have failed a previous treatment with PD-1/PD-L1 immune checkpoint inhibitors (ICI).

Plasticell, a developer of innovative stem cell technologies and cell therapies announced it will collaborate with Anthony Nolan, a leading research organisation dedicated to saving the lives of people with blood cancers, to progress clinical development of Plasticell’s ex vivo expanded cord-blood derived hematopoietic stem cell product.

Orchard Therapeutics , a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, announced the opening of a second facility for technical operations in the San Francisco Bay Area.

Batavia Biosciences announces the expansion of its viral vector process development facilities in the USA and its GMP clean room facilities in the Netherlands to accommodate the increasing market demand.

Recipharm, a leading contract development and manufacturing organisation (CDMO) and Kancera, a development company focused on cancer therapy, have signed a contract for the development and manufacture of the pharmaceutical candidate KAND567.

Multi Packaging Solutions, (MPS), a business of WestRock Company and a leader in value-added print and packaging solutions for the healthcare, branded consumer and multi-media markets, in partnership with Smartglyph, a UK technology business, can now offer customers the ability to allow their packs to ‘talk’ to the consumer.

Contract packaging organisation (CPO), Tjoapack, has launched its new bottle packing line following a major investment earlier this year.

The Sigpack VPF (Vertical Platform for Flat Pouches), the first freely scalable flat pouch machine from Bosch, has been honoured with the German Design Award 2018 in the Excellent Product Design category.